Alivus Life Sciences Ltd.
NSE: ALIVUS
Prev Close
881.4
Open Price
888.65002
Volume
55,174
Today Low / High
879.5 / 899.75
52 WK Low / High
847.2 / 1251
Range
844 - 933
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 888.65, with a change of 7.25 (0.82256%). The expected target range on the NSE is between 844 - 933. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Alivus Life Sciences Ltd. Graph
Alivus Life Sciences Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alivus Life Sciences Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 888.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 888.65 | 897.54 | 807.78 - 987.29 |
| 906.42 | 725.14 - 1,087.71 | ||
| 915.31 | 640.72 - 1,189.90 | ||
| Bearish Scenario | 888.65 | 879.76 | 791.79 - 967.74 |
| 870.88 | 696.70 - 1,045.05 | ||
| 861.99 | 603.39 - 1,120.59 |
Overview of Alivus Life Sciences Ltd.
ISIN
INE03Q201024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
167,469
Market Cap
109,020,779,900
Last Dividend
5
Official Website
IPO Date
2025-01-13
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of ALIVUS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-01 | September 01, 25 | 5 | 5 | 2025-09-01 | 2025-09-12 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial income report data available. | |||||||||||
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 601.85 Cr | 270.39 Cr | 331.46 Cr | 0.5507 | 155.25 Cr | 121.54 Cr | 9.91 | 181.30 Cr | 0.2019 |
| 2025-03-31 | 602.50 Cr | 300.87 Cr | 301.63 Cr | 0.5006 | 184.28 Cr | 141.87 Cr | 0.00 | 208.52 Cr | 0.2355 |
| 2024-12-31 | 641.84 Cr | 285.27 Cr | 356.57 Cr | 0.5555 | 175.15 Cr | 136.96 Cr | 11.18 | 200.76 Cr | 0.2134 |
| 2024-09-30 | 506.88 Cr | 225.20 Cr | 281.68 Cr | 0.5557 | 119.27 Cr | 95.32 Cr | 7.78 | 142.89 Cr | 0.1880 |
| 2024-06-30 | 588.62 Cr | 287.79 Cr | 300.83 Cr | 0.5111 | 145.10 Cr | 111.48 Cr | 9.10 | 164.98 Cr | 0.1894 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 71.06 Cr | 477.62 Cr | 548.68 Cr | 1,009.61 Cr | 673.95 Cr | 2,335.16 Cr | 1,045.72 Cr | 3,411.45 Cr | 594.08 Cr |
| 2024-09-30 | 446.12 Cr | 84.09 Cr | 530.20 Cr | 775.13 Cr | 689.20 Cr | 2,096.06 Cr | 945.12 Cr | 3,084.86 Cr | 546.38 Cr |
| 2024-03-31 | 301.41 Cr | 90.55 Cr | 301.41 Cr | 855.80 Cr | 666.59 Cr | 1,916.00 Cr | 904.78 Cr | 2,850.41 Cr | 518.09 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,794.20 | ₹4,304,886,803,174.00 | ₹1,442,249.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,426.50 | ₹1,706,033,829,370.00 | ₹128,633.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,791.50 | ₹1,283,215,885,760.00 | ₹168,916.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,279.30 | ₹1,065,033,273,233.00 | ₹981,114.00 |
| Lupin Limited | LUPIN | ₹2,112.00 | ₹964,681,344,000.00 | ₹573,967.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹927.45 | ₹933,231,714,026.00 | ₹435,235.00 |
| Mankind Pharma Limited | MANKIND | ₹2,178.80 | ₹899,419,690,874.00 | ₹1,107,712.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,195.10 | ₹694,116,019,647.00 | ₹670,100.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,631.00 | ₹673,270,515,000.00 | ₹35,892.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,968.10 | ₹555,399,412,193.00 | ₹359,544.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,012.30 | ₹546,496,817,959.00 | ₹1,243,204.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,465.90 | ₹371,905,013,166.00 | ₹98,690.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,659.80 | ₹332,303,772,715.00 | ₹81,623.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,798.00 | ₹281,653,104,000.00 | ₹111,646.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,438.60 | ₹272,707,988,894.00 | ₹177,392.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,155.00 | ₹228,875,000,000.00 | ₹2,254.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,341.20 | ₹217,934,497,063.00 | ₹421,135.00 |
| Eris Lifesciences Limited | ERIS | ₹1,572.20 | ₹214,160,196,030.00 | ₹92,545.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,096.00 | ₹206,509,893,344.00 | ₹42,086.00 |
| Cohance Lifesciences Limited | COHANCE | ₹535.80 | ₹204,979,473,612.00 | ₹515,022.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹876.90 | ₹172,366,203,436.00 | ₹49,903.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,086.00 | ₹172,129,300,410.00 | ₹80,321.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹905.05 | ₹162,103,387,844.00 | ₹1,393,984.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,963.90 | ₹149,279,369,774.00 | ₹37,297.00 |
| Granules India Limited | GRANULES | ₹574.50 | ₹139,413,177,342.00 | ₹1,264,501.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹888.65 | ₹109,020,779,900.00 | ₹55,174.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,577.50 | ₹92,583,053,105.00 | ₹4,240.00 |
| Strides Pharma Science Limited | STAR | ₹882.55 | ₹81,347,028,741.00 | ₹94,112.00 |
| FDC Limited | FDC | ₹418.90 | ₹68,201,144,188.00 | ₹69,872.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹740.45 | ₹67,119,788,842.00 | ₹119,729.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹331.75 | ₹64,884,267,458.00 | ₹619,024.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹423.05 | ₹64,769,825,637.00 | ₹167,280.00 |
| Sequent Scientific Limited | SEQUENT | ₹209.68 | ₹52,383,058,368.00 | ₹957,574.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹137.08 | ₹44,485,419,283.00 | ₹1,212,051.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹849.95 | ₹43,108,703,295.00 | ₹33,260.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹390.00 | ₹42,496,453,350.00 | ₹58,924.00 |
| Innova Captab Limited | INNOVACAP | ₹721.40 | ₹41,282,063,781.00 | ₹31,617.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,316.40 | ₹38,310,974,346.00 | ₹5,767.00 |
| Suven Life Sciences Limited | SUVEN | ₹170.65 | ₹37,612,286,460.00 | ₹133,676.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹393.35 | ₹35,901,054,500.00 | ₹120,462.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹348.20 | ₹34,918,368,589.00 | ₹39,213.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹456.00 | ₹32,105,022,000.00 | ₹3,257.00 |
| Hikal Limited | HIKAL | ₹252.71 | ₹31,159,332,533.00 | ₹526,032.00 |
Key Executives
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1965
Gender: male
Year Born:
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about Alivus Life Sciences Ltd.
The CEO is Yasir Yusufali Rawjee.
The current price is ₹888.65.
The range is ₹847.2-1251.
The market capitalization is ₹10,902.08 crores.
The dividend yield is 0.56%.
The P/E ratio is 21.99.
The company operates in the Healthcare sector.
Overview of Alivus Life Sciences Ltd. (ISIN: INE03Q201024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹10,902.08 crores and an average daily volume of 167,469 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.